首页> 美国卫生研究院文献>BioMed Research International >Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases
【2h】

Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases

机译:光动力疗法与咪喹莫特5%乳膏有效结合治疗光化性角化病三例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. The therapy for actinic keratoses includes photodynamic therapy (PDT) and imiquimod 5% cream. The sequential use of both could result in better clinical outcomes. Objectives. To enhance efficacy of therapies while improving tolerability, convenience, and patient adherence with a scheme combining two concomitant or sequential AK treatments. Methods. All patients underwent one session of conventional PDT. Two weeks after, the PDT imiquimod 5% cream was applied to the treatment area once daily for three days per week. One course continued for four weeks followed by a clinical evaluation and decision about further treatment. Patients who had not cleared all of their AK lesions in the treatment area in course 1 participated in a second 4-week course of treatment. Limitations. Small size of population. Results. Three participants were enrolled. Two patients showed complete clinical clearance of AKs. The effect was also noted after long-term followup, at months seven and eleven. No subject discontinued for an adverse event. There were severe local skin reactions in two participants which were severe erythema, scaling, and crusting. One patient showed no response to the therapy. Conclusions. Photodynamic therapy followed by imiquimod was well tolerated and improved reduction of actinic keratoses. This initial proof-of-concept should be studied in larger clinical trials.
机译:背景。光化性角化病的治疗方法包括光动力疗法(PDT)和5%咪喹莫特乳膏。两者的顺序使用可能会导致更好的临床结果。目标。通过结合两种同时或相继AK治疗的方案,提高治疗效果的同时改善耐受性,便利性和患者依从性。方法。所有患者均接受了一次常规PDT治疗。两周后,将PDT咪喹莫特5%乳膏每天一次施用于治疗区域,每周三天。一个疗程持续四个星期,然后进行临床评估并决定进一步治疗。在第1疗程中未清除所有AK病变的患者参加了第二个4周疗程。局限性。人口少。结果。招募了三名参与者。两名患者表现出对AK的完全临床清除。在第7和11个月的长期随访后,也注意到了这种作用。没有受试者因不良事件而中断。两名参与者出现严重的局部皮肤反应,即严重的红斑,脱屑和结cru。一名患者对治疗无反应。结论。接受光动力疗法和咪喹莫特耐受性良好,并改善了光化性角化病的减少。此初始概念验证应在较大的临床试验中进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号